Recently, the research team of Beroni Group has successfully developed a technology that can transform human amniotic epithelial cells into neural stem cells. This innovative approach, which aims to generate new nerve cells and secrete nerve growth factors to protect the nerve tissue of patients, may provide a new therapeutic avenue for the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
Neurodegenerative diseases are characterized by the gradual loss of nerve cells, leading to symptoms that degrade the body’s functions and have a significant impact on the patient’s quality of life. Current treatments for these disorders are limited, with treatment strategies primarily focused on relieving symptoms rather than addressing the underlying cause of the disease. Beroni’s research team has developed a new method for improving the safety of neural stem cells usage in the clinic.
Human amniotic epithelial cells are derived from the amniotic membrane of the placenta and are usually discarded after delivery. These cells have several advantages over other stem cell sources, including abundance, ease of collection, and low immunogenicity. By transforming these cells into neural stem cells and setting up a tumor signal safety monitoring molecular self-destruct mechanism, upon sensing tumor protein signals, this mechanism will activate apoptotic signals, reducing cancer risk treatment, thus improve safety during stem cell treatment of neurodegenerative diseases.
Beroni Group hopes to contribute to the development of a new treatment for neurodegenerative diseases by combining our technologies with recent advances that indicate that neural stem cells may repair damaged cells, secrete inflammatory inhibitory factors and growth factors to further protect nerve cells in patients with neurodegenerative diseases.
